Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809354 · ClinicalTrials.gov registry record · Phase 3
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,720
- Enrollment target
NCT00809354 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,720 participants.
The verdict
NCT00809354, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,720 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
Interventions
- DRUG NSAID
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,720 participants |
| Start Date | 2009-02-12 |
| Est. Completion | 2011-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809354
The ClinicalTrials.gov registry entry for NCT00809354 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NSAID is the first listed.
NCT00809354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809354 about?
NCT00809354 is a clinical study titled "Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip". The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
What is the current status of trial NCT00809354?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,720 participants. The study started on 2009-02-12. Estimated completion is 2011-01-12.
What interventions are being tested in trial NCT00809354?
The interventions under investigation include: NSAID (DRUG), tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00809354?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.